Nabil Fakih-Gomez
Research Subjects
Nabil Fakih-Gomez has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
Cristina Muñoz-Gonzalez
Department of Facial Plastic and Cranio-Maxillo-Facial Surgery, Fakih Hospital, Khaizaran, Lebanon
20 shared publicationsLessandro Martins
10 shared publicationsIbrahim Fakih-Gomez
Fakih Hospital, Khaizaran, Lebanon
9 shared publicationsJonathan Kadouch
Practice for Aesthetic Dermatology, ReSculpt Clinic, Amsterdam, The Netherlands
7 shared publications- Jonathan Kadouch
Practice for Aesthetic Dermatology, ReSculpt Clinic, Amsterdam, The Netherlands
6 shared publications - Juan Martin Zarate
Fakih Hospital, Khaizaran, Lebanon
6 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Elsevier in JPRAS Open
- Vol. 53, 108-118
Sonographic evolution of customized CaHA-CMC:CPM hybrid dermal fillers: a six-month high-frequency ultrasound case series
- 30 October 2026
- Published by Elsevier in JPRAS Open
- Vol. 53, 108-118
Open AccessSonographic evolution of customized CaHA-CMC:CPM hybrid dermal fillers: a six-month high-frequency ultrasound case series
- Open Access
- 1 October 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-14
Injector Experience and Satisfaction with a Redesigned Syringe for Cohesive Polydensified Matrix Gels: A Non-Comparative Questionnaire-Based Study
Background: Clinician-reported evaluations of syringe injectability and handling during hyaluronic acid (HA) filler administration remain limited. Objective: To characterize experienced injectors’ perceptions of the usability, handling, and safety-related features of a redesigned (Gen2) syringe for cohesive polydensified matrix (CPM) HA gels. Methods: In this retrospective, non-comparative analysis of a manufacturer-associated questionnaire evaluation, 17 experienced Key Opinion Leaders (KOLs), including nine manuscript authors, evaluated the Gen2 syringe following clinical use (n=12) or simulated use (n=5). The Gen2 syringe and CPM products were provided by the manufacturer. Participants completed a study-specific questionnaire reviewed for clarity, clinical relevance, and face validity and provided qualitative feedback regarding syringe ergonomics, handling, extrusion characteristics, injection control, and perceived safety-related features. No comparator syringe was evaluated. Questionnaire responses were summarized using descriptive statistics, with exact 95% confidence intervals calculated for selected proportions. Results: Injectors generally rated the evaluated syringe attributes favorably. The integrated Luer-lock was selected as a valuable design feature by 13/17 respondents (76.5%), followed by perceived lower extrusion force (11/17, 64.7%) and the concave thumb grip (9/17, 52.9%). Responses were predominantly favorable regarding perceived injection-volume accuracy and reduction in needle-detachment risk. Five of 17 respondents (29.4%) reported usability considerations, including scale orientation, syringe length, and resistance during rubber-bung removal. Conclusion: The redesigned syringe was rated favorably by this small, selected group of experienced injectors familiar with the legacy platform. These exploratory, perception-based findings should be interpreted in the context of the non-comparative design, sponsor-associated participant selection and use of a study-specific questionnaire developed for this evaluation. Comparative studies incorporating objective performance measures are warranted.
- 1 October 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-14
Open AccessInjector Experience and Satisfaction with a Redesigned Syringe for Cohesive Polydensified Matrix Gels: A Non-Comparative Questionnaire-Based Study
Background: Clinician-reported evaluations of syringe injectability and handling during hyaluronic acid (HA) filler administration remain limited. Objective: To characterize experienced injectors’ perceptions of the usability, handling, and safety-related features of a redesigned (Gen2) syringe for cohesive polydensified matrix (CPM) HA gels. Methods: In this retrospective, non-comparative analysis of a manufacturer-associated questionnaire evaluation, 17 experienced Key Opinion Leaders (KOLs), including nine manuscript authors, evaluated the Gen2 syringe following clinical use (n=12) or simulated use (n=5). The Gen2 syringe and CPM products were provided by the manufacturer. Participants completed a study-specific questionnaire reviewed for clarity, clinical relevance, and face validity and provided qualitative feedback regarding syringe ergonomics, handling, extrusion characteristics, injection control, and perceived safety-related features. No comparator syringe was evaluated. Questionnaire responses were summarized using descriptive statistics, with exact 95% confidence intervals calculated for selected proportions. Results: Injectors generally rated the evaluated syringe attributes favorably. The integrated Luer-lock was selected as a valuable design feature by 13/17 respondents (76.5%), followed by perceived lower extrusion force (11/17, 64.7%) and the concave thumb grip (9/17, 52.9%). Responses were predominantly favorable regarding perceived injection-volume accuracy and reduction in needle-detachment risk. Five of 17 respondents (29.4%) reported usability considerations, including scale orientation, syringe length, and resistance during rubber-bung removal. Conclusion: The redesigned syringe was rated favorably by this small, selected group of experienced injectors familiar with the legacy platform. These exploratory, perception-based findings should be interpreted in the context of the non-comparative design, sponsor-associated participant selection and use of a study-specific questionnaire developed for this evaluation. Comparative studies incorporating objective performance measures are warranted.
- 9 September 2026
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 50 (19) , 7864-7878
Infra-Brow Volume Contouring Surgery
Introduction The periorbital region plays a key role in facial aging, with notable ethnic variations in brow and eyelid morphology. Eurodescendientes patients with high or normal eyebrow positions often present with excess infra-brow volume and lateral hooding. The infra-brow volume contouring fat lift surgery was developed to address this condition by integrating principles from previously described Asian sub-brow blepharoplasty methods, adapted to Eurodescendientes anatomy. Materials and Methods A retrospective study was conducted on 40 Eurodescendientes female patients (mean age: 39.5 years) who underwent this surgical technique between October 2023 and October 2024. The procedure consisted of a five-step technique: elliptical skin and subcutaneous excision, en bloc removal of the orbicularis oculi muscle (OOM) and retro-orbicularis oculi fat (ROOF), contouring of the remanent ROOF, fixation of the lower muscle flap through the sub-frontalis fascia to the supraorbital rim periosteum using absorbable sutures, followed by layered muscle and skin closure. Postoperative outcomes were assessed over a follow-up period ranging from 11 to 19 months, focusing on patient satisfaction, scar appearance, and complications. Results All patients demonstrated satisfactory esthetic outcomes, with a 100% reported satisfaction rate. Postoperative swelling resolved within 1–3 months, and no unaesthetic scars were observed. Transient sensory symptoms, including paresthesia and hypoesthesia, occurred in all cases but resolved within 3–5 months. No permanent sensory deficits or major complications were reported. Conclusion This technique provides an effective, stable, and esthetically reliable correction for infra-brow bulging in patients with high or normal eyebrow positions. Combining all five steps of the technique ensures durable results and minimal scarring. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
- 9 September 2026
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 50 (19) , 7864-7878
Infra-Brow Volume Contouring Surgery
Introduction The periorbital region plays a key role in facial aging, with notable ethnic variations in brow and eyelid morphology. Eurodescendientes patients with high or normal eyebrow positions often present with excess infra-brow volume and lateral hooding. The infra-brow volume contouring fat lift surgery was developed to address this condition by integrating principles from previously described Asian sub-brow blepharoplasty methods, adapted to Eurodescendientes anatomy. Materials and Methods A retrospective study was conducted on 40 Eurodescendientes female patients (mean age: 39.5 years) who underwent this surgical technique between October 2023 and October 2024. The procedure consisted of a five-step technique: elliptical skin and subcutaneous excision, en bloc removal of the orbicularis oculi muscle (OOM) and retro-orbicularis oculi fat (ROOF), contouring of the remanent ROOF, fixation of the lower muscle flap through the sub-frontalis fascia to the supraorbital rim periosteum using absorbable sutures, followed by layered muscle and skin closure. Postoperative outcomes were assessed over a follow-up period ranging from 11 to 19 months, focusing on patient satisfaction, scar appearance, and complications. Results All patients demonstrated satisfactory esthetic outcomes, with a 100% reported satisfaction rate. Postoperative swelling resolved within 1–3 months, and no unaesthetic scars were observed. Transient sensory symptoms, including paresthesia and hypoesthesia, occurred in all cases but resolved within 3–5 months. No permanent sensory deficits or major complications were reported. Conclusion This technique provides an effective, stable, and esthetically reliable correction for infra-brow bulging in patients with high or normal eyebrow positions. Combining all five steps of the technique ensures durable results and minimal scarring. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
- 25 August 2026
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 50 (19) , 8039-8047
A Three-Point, Low-Dose, Artery-Targeted Botulinum Toxin Treatment for Chronic Migraine: A Randomized, Double-Blind, Contralateral-Controlled Trial
Introduction Migraine is a prevalent neurovascular disorder with complex neural and vascular mechanisms. Botulinum toxin type A (BoNT-A) is an established preventive treatment for chronic migraine, yet its vascular effects remain unclear. This study investigated whether targeted BoNT-A injections along migraine-related arteries reduce headache intensity and alter vascular diameter. Materials and Methods In this prospective, randomized, double-blind, controlled trial, 23 adults with chronic migraine received BoNT-A injections on one side of the head and saline on the contralateral side. Three injection points were placed along the superficial temporal artery (STA). Ultrasound measurements of the STA (proximal and distal) and supraorbital (SO) arteries were obtained at baseline, 1 h, 2 weeks, and 2 months. Pain intensity was assessed using a 10-point Visual Analogue Scale (VAS). Results Mean VAS scores on the BoNT-A–treated side decreased significantly from 8.7 ± 1.46 at baseline to 2.65 ± 1.15 at 2 months (p < 0.001). No significant vascular diameter changes were detected in the STA or SO arteries between treatment and control sides (p < 0.05). No adverse events were reported. Conclusion Artery-targeted BoNT-A injections produced a significant reduction in migraine pain without measurable arterial dilation, suggesting that therapeutic effects are mediated primarily through neural and neurochemical modulation rather than vascular diameter changes. This low-dose, artery-focused approach may represent a safe, efficient refinement of current migraine injection protocols. Level of Evidence II This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
- 25 August 2026
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 50 (19) , 8039-8047
A Three-Point, Low-Dose, Artery-Targeted Botulinum Toxin Treatment for Chronic Migraine: A Randomized, Double-Blind, Contralateral-Controlled Trial
Introduction Migraine is a prevalent neurovascular disorder with complex neural and vascular mechanisms. Botulinum toxin type A (BoNT-A) is an established preventive treatment for chronic migraine, yet its vascular effects remain unclear. This study investigated whether targeted BoNT-A injections along migraine-related arteries reduce headache intensity and alter vascular diameter. Materials and Methods In this prospective, randomized, double-blind, controlled trial, 23 adults with chronic migraine received BoNT-A injections on one side of the head and saline on the contralateral side. Three injection points were placed along the superficial temporal artery (STA). Ultrasound measurements of the STA (proximal and distal) and supraorbital (SO) arteries were obtained at baseline, 1 h, 2 weeks, and 2 months. Pain intensity was assessed using a 10-point Visual Analogue Scale (VAS). Results Mean VAS scores on the BoNT-A–treated side decreased significantly from 8.7 ± 1.46 at baseline to 2.65 ± 1.15 at 2 months (p < 0.001). No significant vascular diameter changes were detected in the STA or SO arteries between treatment and control sides (p < 0.05). No adverse events were reported. Conclusion Artery-targeted BoNT-A injections produced a significant reduction in migraine pain without measurable arterial dilation, suggesting that therapeutic effects are mediated primarily through neural and neurochemical modulation rather than vascular diameter changes. This low-dose, artery-focused approach may represent a safe, efficient refinement of current migraine injection protocols. Level of Evidence II This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
- Open Access
- 19 August 2026
- Published by Elsevier in JPRAS Open
- Vol. 52, 196-205
The role of nanofat membranes in inhibiting bacterial growth: An in vitro analysis
- 19 August 2026
- Published by Elsevier in JPRAS Open
- Vol. 52, 196-205
Open AccessThe role of nanofat membranes in inhibiting bacterial growth: An in vitro analysis
- 28 March 2026
- Published by SAGE Publications in The American Journal of Cosmetic Surgery
- Vol. 43 (3) , 332-338
Caves Maneuver in Deep Plane Facelift and Necklift Dissection
Introduction: Facelift surgery is a key procedure for facial rejuvenation, with deep plane facelifts providing long-lasting aesthetic improvements. The proposed Caves maneuver is a dissection technique to enhance surgical time efficiency and minimize risks in deep plane facelift procedures. Methods: A prospective study included 123 patients who underwent deep plane facelift and neck lift procedures from January 1, 2023, to December 1, 2024. Sixty-three patients (group 1) underwent the deep plane surgery with Caves maneuver, while 60 patients (group 2) received the traditional deep plane surgery without the Caves maneuver. Demographic data, operative times, and complications were analyzed. Results: Group 1 consisted of 63 patients (87.3% women and 12.7% men), while group 2 consisted of 60 patients (98.3% women and 1.7% men). Group 1 had a significantly shorter deep plane dissection time (9.5 minutes, range = 8-10 minutes) compared with group 2 (23 minutes, range = 20-25 minutes). Complications included 1 case of hematoma in group 2, 8 cases of temporary paresis of the marginal mandibular nerve, and 7 cases of hypertrophic scarring. No infections were reported. Group 1 demonstrated a lower incidence of complications, and in relation to nerve paresis, group 1 (1 case; 1.5%) had a lower incidence compared with group 2 (7 cases; 11.6%). Conclusion: The Caves maneuver significantly reduced dissection time and showed a lower incidence of nerve paresis. Complications were minimal, suggesting that the Caves maneuver is a safe and effective modification. Further studies with larger cohorts are recommended to validate these results.
- 28 March 2026
- Published by SAGE Publications in The American Journal of Cosmetic Surgery
- Vol. 43 (3) , 332-338
Caves Maneuver in Deep Plane Facelift and Necklift Dissection
Introduction: Facelift surgery is a key procedure for facial rejuvenation, with deep plane facelifts providing long-lasting aesthetic improvements. The proposed Caves maneuver is a dissection technique to enhance surgical time efficiency and minimize risks in deep plane facelift procedures. Methods: A prospective study included 123 patients who underwent deep plane facelift and neck lift procedures from January 1, 2023, to December 1, 2024. Sixty-three patients (group 1) underwent the deep plane surgery with Caves maneuver, while 60 patients (group 2) received the traditional deep plane surgery without the Caves maneuver. Demographic data, operative times, and complications were analyzed. Results: Group 1 consisted of 63 patients (87.3% women and 12.7% men), while group 2 consisted of 60 patients (98.3% women and 1.7% men). Group 1 had a significantly shorter deep plane dissection time (9.5 minutes, range = 8-10 minutes) compared with group 2 (23 minutes, range = 20-25 minutes). Complications included 1 case of hematoma in group 2, 8 cases of temporary paresis of the marginal mandibular nerve, and 7 cases of hypertrophic scarring. No infections were reported. Group 1 demonstrated a lower incidence of complications, and in relation to nerve paresis, group 1 (1 case; 1.5%) had a lower incidence compared with group 2 (7 cases; 11.6%). Conclusion: The Caves maneuver significantly reduced dissection time and showed a lower incidence of nerve paresis. Complications were minimal, suggesting that the Caves maneuver is a safe and effective modification. Further studies with larger cohorts are recommended to validate these results.
- 16 March 2026
- Published by Springer Nature in Aesthetic Plastic Surgery
- p. 1-18
Guide for Managing Vascular Occlusion Due to Fillers with Extended Neuro-Ophthalmic Involvement: A Review of Diagnosis, Classification and Treatment
Introduction Filler-induced ophthalmic vascular occlusion (FIVO) is rare but devastating, while stroke remains even less frequent. Hyaluronic acid (HA) accounts for most reported cases of blindness. Given the emergency nature of these events, rapid recognition and immediate preparedness are paramount. Methods A systematic search of PubMed, Web of Science, and the Cochrane Library was conducted up to August 2025 in accordance with PRISMA 2020 guidelines. Studies addressing vascular occlusion with neuro-ophthalmic involvement from dermal fillers, including technical and pharmacological management, were reviewed. After screening 48 records, 35 articles met inclusion criteria. Expert consensus statements and recommendations from international panels were also incorporated. Results Three thematic domains emerged: etiology, classification, and management. Embolic events occur immediately via direct intra-arterial injection or later through embolus fragmentation, migration, or arteriovenous shunting. Temporal classification distinguishes fulminant, immediate, and delayed presentations with distinct prognostic implications. Ophthalmic involvement typically manifests as vision loss, ptosis, or ophthalmoplegia, while neurological complications, including stroke, occur in up to 24% of cases, often affecting the middle cerebral artery. Imaging provides critical diagnostic and therapeutic guidance. Hyaluronidase (HYAL) remains the only intervention consistently associated with improved outcomes, though the optimal delivery route (extraorbital, peribulbar, retrobulbar) remains debated. Adjunctive measures include intraocular pressure reduction, ocular massage, antiplatelet therapy, and hyperbaric oxygen. Conclusion FIVO is a time-critical emergency. Early intervention with HYAL and supportive measures at the point of care, followed by rapid referral for advanced ophthalmic and neurological evaluation, is essential. Standardized guidelines are urgently needed to harmonize practice and improve patient outcomes. Level of Evidence V This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
- 16 March 2026
- Published by Springer Nature in Aesthetic Plastic Surgery
- p. 1-18
Guide for Managing Vascular Occlusion Due to Fillers with Extended Neuro-Ophthalmic Involvement: A Review of Diagnosis, Classification and Treatment
Introduction Filler-induced ophthalmic vascular occlusion (FIVO) is rare but devastating, while stroke remains even less frequent. Hyaluronic acid (HA) accounts for most reported cases of blindness. Given the emergency nature of these events, rapid recognition and immediate preparedness are paramount. Methods A systematic search of PubMed, Web of Science, and the Cochrane Library was conducted up to August 2025 in accordance with PRISMA 2020 guidelines. Studies addressing vascular occlusion with neuro-ophthalmic involvement from dermal fillers, including technical and pharmacological management, were reviewed. After screening 48 records, 35 articles met inclusion criteria. Expert consensus statements and recommendations from international panels were also incorporated. Results Three thematic domains emerged: etiology, classification, and management. Embolic events occur immediately via direct intra-arterial injection or later through embolus fragmentation, migration, or arteriovenous shunting. Temporal classification distinguishes fulminant, immediate, and delayed presentations with distinct prognostic implications. Ophthalmic involvement typically manifests as vision loss, ptosis, or ophthalmoplegia, while neurological complications, including stroke, occur in up to 24% of cases, often affecting the middle cerebral artery. Imaging provides critical diagnostic and therapeutic guidance. Hyaluronidase (HYAL) remains the only intervention consistently associated with improved outcomes, though the optimal delivery route (extraorbital, peribulbar, retrobulbar) remains debated. Adjunctive measures include intraocular pressure reduction, ocular massage, antiplatelet therapy, and hyperbaric oxygen. Conclusion FIVO is a time-critical emergency. Early intervention with HYAL and supportive measures at the point of care, followed by rapid referral for advanced ophthalmic and neurological evaluation, is essential. Standardized guidelines are urgently needed to harmonize practice and improve patient outcomes. Level of Evidence V This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
- 9 February 2026
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 50 (11) , 4240-4250
Botulinum Toxin Vascular Effectiveness: Low or High Doses?
Introduction Botulinum toxin (BoNT) is increasingly recognized for vascular effects beyond its established neuromuscular use. Evidence indicates a dose-dependent mechanism in which BoNT either promotes vasodilation and perfusion or inhibits cholinergic vasodilatory activity, making it relevant for ischemic, vasospastic, and inflammatory conditions. This review evaluates current data on the dose-dependent vascular actions of BoNT and outlines its therapeutic relevance in aesthetic and reconstructive medicine. Materials and Methods A narrative review was performed using PubMed, MEDLINE, Embase, and Google Scholar, focusing on studies published from 2000 to 2025. Search terms combined “botulinum toxin” with “vasodilation,” “ischemia,” “flap survival,” “angiogenesis,” and related concepts. Eligible publications included clinical trials, animal studies, in vitro models, and systematic reviews assessing vascular outcomes after BoNT exposure. Of 163 records identified, 57 met inclusion criteria and were analyzed. Results BoNT demonstrates dual vascular mechanisms. At higher doses, it enhances perfusion and promotes angiogenesis through vascular endothelial growth factor and nitric oxide pathways, supporting applications in ischemic flaps and Raynaud’s phenomenon. At lower doses, it reduces excessive cholinergic vasodilation and neurogenic inflammation, offering benefits in conditions such as rosacea and hyperhidrosis. These effects are dose-dependent and tissue-specific, with variability across experimental models. Concentrations above 20 IU/ml may be considered high-dose, whereas lower levels represent low-dose BoNT. Conclusion BoNT exhibits versatile vascular activity. Higher doses support vascular regeneration and angiogenesis, while lower doses modulate hyperreactive vascular responses. Further research is needed to clarify mechanisms, refine dose-response guidelines, and assess long-term safety across clinical indications to optimize its vascular applications. Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266
- 9 February 2026
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 50 (11) , 4240-4250
Botulinum Toxin Vascular Effectiveness: Low or High Doses?
Introduction Botulinum toxin (BoNT) is increasingly recognized for vascular effects beyond its established neuromuscular use. Evidence indicates a dose-dependent mechanism in which BoNT either promotes vasodilation and perfusion or inhibits cholinergic vasodilatory activity, making it relevant for ischemic, vasospastic, and inflammatory conditions. This review evaluates current data on the dose-dependent vascular actions of BoNT and outlines its therapeutic relevance in aesthetic and reconstructive medicine. Materials and Methods A narrative review was performed using PubMed, MEDLINE, Embase, and Google Scholar, focusing on studies published from 2000 to 2025. Search terms combined “botulinum toxin” with “vasodilation,” “ischemia,” “flap survival,” “angiogenesis,” and related concepts. Eligible publications included clinical trials, animal studies, in vitro models, and systematic reviews assessing vascular outcomes after BoNT exposure. Of 163 records identified, 57 met inclusion criteria and were analyzed. Results BoNT demonstrates dual vascular mechanisms. At higher doses, it enhances perfusion and promotes angiogenesis through vascular endothelial growth factor and nitric oxide pathways, supporting applications in ischemic flaps and Raynaud’s phenomenon. At lower doses, it reduces excessive cholinergic vasodilation and neurogenic inflammation, offering benefits in conditions such as rosacea and hyperhidrosis. These effects are dose-dependent and tissue-specific, with variability across experimental models. Concentrations above 20 IU/ml may be considered high-dose, whereas lower levels represent low-dose BoNT. Conclusion BoNT exhibits versatile vascular activity. Higher doses support vascular regeneration and angiogenesis, while lower doses modulate hyperreactive vascular responses. Further research is needed to clarify mechanisms, refine dose-response guidelines, and assess long-term safety across clinical indications to optimize its vascular applications. Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266
- Open Access
- 30 January 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (2) , e70688
Real‐World Usage of CaHA ‐ CMC : CPM ‐ HA Hybrid Dermal Fillers: Findings From a Delphi Panel
Background: The popularity of minimally invasive aesthetic procedures has increased globally, with a 40.9% increase in non‐surgical procedures between 2019 and 2023. Dermal fillers have gained popularity for delivering visible results with short recovery times. Among these, hybrid dermal fillers combining calcium hydroxylapatite‐carboxymethyl cellulose (CaHA‐CMC) and cohesive polydensified matrix‐hyaluronic acid (CPM‐HA) offer tailored treatment with demonstrated efficacy and tolerability. However, standardized guidance for use remains limited. Objective: To establish consensus among a panel of aesthetic healthcare professionals (HCPs) on the real‐world use of CaHA‐CMC:CPM‐HA hybrid dermal fillers. Methods: A modified Delphi process was conducted with 23 international HCPs. Statements were developed from scientific advisory board outcomes and a literature review, refined by a scientific steering committee and evaluated across three rounds. Consensus was defined as ≥ 80% agreement/disagreement. Results: Consensus was reached on the safety, efficacy, and use of CaHA‐CMC:CPM‐HA hybrid dermal fillers for volumization, contouring, and skin quality improvement. Of 43 statements, 27 reached consensus in Round 1, 7 in Round 2, and 3 in Round 3. Recommendations included dilution ratios, the “foaming” technique, subdermal injection, and avoiding high muscle activity sites. Experts highlighted the synergistic effects and convenience of CaHA‐CMC:CPM‐HA fillers, while noting the need for further research on long‐term safety and rheological properties. Conclusion: These results provide a base for standardized hybrid dermal filler use. Agreement on topics including indications, efficacy, and safety underscore the experts' unified stance on hybrid dermal filler usage. These consensus statements can serve as guidelines to ensure effective and safe clinical practice.
- 30 January 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (2) , e70688
Open AccessReal‐World Usage of CaHA ‐ CMC : CPM ‐ HA Hybrid Dermal Fillers: Findings From a Delphi Panel
Background: The popularity of minimally invasive aesthetic procedures has increased globally, with a 40.9% increase in non‐surgical procedures between 2019 and 2023. Dermal fillers have gained popularity for delivering visible results with short recovery times. Among these, hybrid dermal fillers combining calcium hydroxylapatite‐carboxymethyl cellulose (CaHA‐CMC) and cohesive polydensified matrix‐hyaluronic acid (CPM‐HA) offer tailored treatment with demonstrated efficacy and tolerability. However, standardized guidance for use remains limited. Objective: To establish consensus among a panel of aesthetic healthcare professionals (HCPs) on the real‐world use of CaHA‐CMC:CPM‐HA hybrid dermal fillers. Methods: A modified Delphi process was conducted with 23 international HCPs. Statements were developed from scientific advisory board outcomes and a literature review, refined by a scientific steering committee and evaluated across three rounds. Consensus was defined as ≥ 80% agreement/disagreement. Results: Consensus was reached on the safety, efficacy, and use of CaHA‐CMC:CPM‐HA hybrid dermal fillers for volumization, contouring, and skin quality improvement. Of 43 statements, 27 reached consensus in Round 1, 7 in Round 2, and 3 in Round 3. Recommendations included dilution ratios, the “foaming” technique, subdermal injection, and avoiding high muscle activity sites. Experts highlighted the synergistic effects and convenience of CaHA‐CMC:CPM‐HA fillers, while noting the need for further research on long‐term safety and rheological properties. Conclusion: These results provide a base for standardized hybrid dermal filler use. Agreement on topics including indications, efficacy, and safety underscore the experts' unified stance on hybrid dermal filler usage. These consensus statements can serve as guidelines to ensure effective and safe clinical practice.
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
The Efficacy of High‐Dose Pulsed Hyaluronidase in Ischemia Following Hyaluronic Acid Fillers: A Retrospective Study of 47 Patients
Background: Hyaluronic acid (HA) injections, primarily used as dermal fillers, have become popular over the past 2 decades. However, filler injections can lead to severe complications, such as ischemia, with hyaluronidase (HYAL) being the primary treatment. Objectives: The study aimed to evaluate the effects of the high‐dose pulsed hyaluronidase (HDPH) protocol, which involves administering repeated doses of HYAL exceeding 500 IU. Methods: A retrospective observational study was conducted in a private clinic between 2018 and 2023, analyzing 47 cases divided into two groups: Group A, treated with the HDPH protocol, and Group B, which served as the natural history comparison cohort illustrating outcomes associated with delayed presentation and received the palliative therapeutic regimen. Results: In Group A ( n = 29), advanced ischemia was significantly associated with scar formation ( p = 0.01). Patients treated with HDPH (Group A) had a lower rate of scar formation (13.8%), while all receiving palliative therapies experienced scar formation (Group B) (100%). Overall, the HDPH protocol is associated with reduced scar formation. Conclusion: The study highlights the potential role of the HDPH protocol in the management of ischemia. Early administration of HDPH improves clinical outcomes, highlighting the importance of physician training in its application for vascular‐related ischemia. Routine follow‐up after filler injections is essential for the early detection and timely treatment of ischemia.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Open AccessThe Efficacy of High‐Dose Pulsed Hyaluronidase in Ischemia Following Hyaluronic Acid Fillers: A Retrospective Study of 47 Patients
Background: Hyaluronic acid (HA) injections, primarily used as dermal fillers, have become popular over the past 2 decades. However, filler injections can lead to severe complications, such as ischemia, with hyaluronidase (HYAL) being the primary treatment. Objectives: The study aimed to evaluate the effects of the high‐dose pulsed hyaluronidase (HDPH) protocol, which involves administering repeated doses of HYAL exceeding 500 IU. Methods: A retrospective observational study was conducted in a private clinic between 2018 and 2023, analyzing 47 cases divided into two groups: Group A, treated with the HDPH protocol, and Group B, which served as the natural history comparison cohort illustrating outcomes associated with delayed presentation and received the palliative therapeutic regimen. Results: In Group A ( n = 29), advanced ischemia was significantly associated with scar formation ( p = 0.01). Patients treated with HDPH (Group A) had a lower rate of scar formation (13.8%), while all receiving palliative therapies experienced scar formation (Group B) (100%). Overall, the HDPH protocol is associated with reduced scar formation. Conclusion: The study highlights the potential role of the HDPH protocol in the management of ischemia. Early administration of HDPH improves clinical outcomes, highlighting the importance of physician training in its application for vascular‐related ischemia. Routine follow‐up after filler injections is essential for the early detection and timely treatment of ischemia.